Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH)

Hua Han; Yanmin Liu; Bing Yu

doi:10.47297/wspbdsWSP2752-630519.20260601

PDF
导出
分享
收藏
专辑

Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH)

6卷第1期

浏览量: 0 Downloads: 0

Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH)
Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH)
1.Department of Gradute School,Qinghai University, Xining, Qinghai, 810007, China
Department of Cardiovascular Medicine, Qinghai Provincial People's Hospital, Xining, Qinghai, 810007, China
3.Qiqihar First Hospital, Heilongjiang, Qiqihar, 161000 ,China
2026年6卷第1期页码：87-89
纸质出版：2026-03-30
DOI：10.47297/wspbdsWSP2752-630519.20260601
Accepted：

Scan QR Code

Hua Han, Yanmin Liu & Bing Yu. (2026). Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH). 生物医学大数据, 6(1), 87-89.

Han Hua,Liu Yanmin,Yu Bing.Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH)[J].Biomedical Data Science,2026,06(01):87-89.
Hua Han, Yanmin Liu & Bing Yu. (2026). Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH). 生物医学大数据, 6(1), 87-89. DOI： 10.47297/wspbdsWSP2752-630519.20260601.

Han Hua,Liu Yanmin,Yu Bing.Recent Research Progress in the Management of High-Altitude Pulmonary Hypertension (HAPH)[J].Biomedical Data Science,2026,06(01):87-89. DOI： 10.47297/wspbdsWSP2752-630519.20260601.

摘要

Abstract

High-altitude pulmonary hypertension (HAPH) is a life-threatening disorder caused by hypobaric hypoxia at high altitudes. This review summarizes the latest advances in the pathogenesis and management of HAPH. The pathogenesis mainly involves hypobaric hypoxia

persistent pulmonary arteriolar constriction

smooth muscle cell proliferation

and vascular remodeling. Current therapeutic strategies include pharmacotherapy (PDE-5 inhibitors

endothelin receptor antagonists

prostacyclins

traditional Chinese medicine

and Tibetan medicine)

oxygen therapy

and surgical interventions such as pulmonary arterial denervation and transplantation. This paper aims to provide updated evidence and clinical insights for the prevention and treatment of HAPH in high-altitude residents and travelers.

关键词

Keywords

references

Sydykov A. , Mamazhakypov A. , Wilkinson J. M. , & Krymskaya V . P . ( 2021 ). Pulmonary hypertension in acute and chronic high altitude maladaptation disorders. International Journal of Environmental Research and Public Health , 18 ( 4 ), 1692 .

Negi P. C. , Marwaha R. , Asotra S. , & Ganju N . ( 2014 ). Prevalence of high altitude pulmonary hypertension among the natives of Spiti Valley—a high altitude region in Himachal Pradesh . High Altitude Medicine & Biology , 15 ( 4 ), 504 – 510 .

Soria R. , Egger M. , Scherrer U. , & Vazquez S . ( 2019 ). Pulmonary arterial pressure at rest and during exercise in chronic mountain sickness: a meta-analysis . European Respiratory Journal , 53 ( 6 ), 1802040 .

Shi C. Y. , Zhai H. Y. , Liu S. J. , & Tang W . F . ( 2024 ). Research progress on soluble guanylate cyclase stimulators and activators. Progress in Pharmaceutical Sciences , 48 ( 9 ), 707 – 715 .

Feng E. Z. , Huang N. X. , Yang S. Y. , Yin H. , Tian Z. X. , & Zhang Y . ( 2016 ). Correlation between hypoxic pulmonary hypertension and pulmonary vascular endothelial function at high altitude . Chinese Journal of Lung Diseases (Electronic Edition) , 9 ( 3 ), 248 – 251 .

Simonneau G. , Montani D. , Celermajer D. S. , Denton C. P. , Gatzoulis M. A. , Krowka M. J. , ... & Souza , R . 2019 . Haemodynamic definitions and updated clinical classification of pulmonary hypertension. European Respiratory Journal, 53 ( 1 ), 1801913 .

West J . B . ( 2016 ). Early history of high-altitude physiology. Annals of the New York Academy of Sciences , 1365 ( 1 ), 33 – 42 .

Mirrakhimov A. E. , & Strohl K . P . ( 2016 ). High-altitude pulmonary hypertension: an update on disease pathogenesis and management. Open Cardiovascular Medicine Journal , 10 , 19 – 27 .

Prasad H. , Mathew J . K . K., & Visweswariah S . S . 2022 . Receptor guanylate cyclase C and cyclic GMP in health and disease: perspectives and therapeutic opportunities. Frontiers in Endocrinology, 13, 911459 .

Pieske B. , Maggioni A. P. , Lam C . S . P., Anand I. , Böhm M., Chiang C. E., ... & Zannad, F . 2017 . Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOCRATES-PRESERVED study. European Heart Journal, 38 ( 15 ), 1119 – 1127 .

Yang Z. W. , Wang Z. M. , Li S. , Zou J. , & He X . L . ( 2024 ). Advances in treatment of chronic thromboembolic pulmonary hypertension. Chinese Journal of Cardiovascular Medicine , 29 ( 3 ), 278 – 282 .

Cui W . J . ( 2021 ). Efficacy and safety of sildenafil in the treatment of high altitude heart disease complicated with severe pulmonary hypertension. Smart Health , 7 ( 12 ), 186 – 188, 191 .

Zhao B. G. , & Zhang B . L . ( 2020 ). Clinical study on early drug treatment of high altitude pulmonary hypertension. Qinghai Medical Journal , 50 ( 2 ), 6 – 8 .

Wang J. Q. , Li W. H. , & Chen Y . C . ( 2023 ). Research progress of high altitude pulmonary hypertension. Chinese Journal of Cardiovascular Medicine , 28 ( 6 ), 601 – 606 .

Liu X. Y. , Chen X. S. , & Luo Y . J . ( 2020 ). Research progress of bosentan in prevention and treatment of high altitude pulmonary hypertension. Medical Journal of Chinese People's Liberation Army , 63 ( 1 ), 79 – 83 .

Cui X . D . ( 2024 ). Non-targeted metabolomics study of plasma in high altitude pulmonary hypertension rats based on UPLC-MS technology (Master's thesis). Gansu University of Chinese Medicine , Lanzhou.

Hu D. L. , & Liu S . ( 2022 ). Effects of alprostadil combined with milrinone on expression of endothelin-1 and vascular cell adhesion molecule-1 and hemodynamics in children with congenital heart disease complicated with pulmonary hypertension . Maternal and Child Health Care of China , 37 ( 23 ), 4398 – 4401 .

Zhang Y. K. , & Shu Y . G . ( 2011 ). Pharmacological effects and clinical application of traditional Chinese medicine in prevention and treatment of high altitude diseases. Journal of High Altitude Medicine , 21 ( 1 ), 57 – 62 .

Wang M. M. , Wu G. Z. , Maimaitiyiming D. , Yang T. , & Aikemu A . ( 2019 ). Intervention effect of jujube extract on high altitude pulmonary hypertension model rats and its improvement effect on cardiac injury . Hebei Journal of Traditional Chinese Medicine , 41 ( 8 ), 1225 – 1229 , 1270 .

Mu X. Y. , & Hua M . ( 2020 ). Correlation analysis of interleukin-6, nuclear factor-κB and chronic obstructive pulmonary disease complicated with pulmonary hypertension at high altitude . World Latest Medicine Information , 20 ( 104 ), 140 – 141 .

Wang Y. F. , Wang A. X. , Wang S. B. , Duo D. L. , Li Q. , & Yan Y . J . ( 2019 ). Intervention effect and mechanism of Salvia przewalskii on high altitude pulmonary hypertension in rats. Chinese Journal of Applied Physiology , 35 ( 6 ), 533 – 536 .

Fan L. , Zhang W. , & Zeng J . P . ( 2025 ). Exploring active ingredients and molecular targets of Compound Danshen Dripping Pills in preventing acute mountain sickness based on network pharmacology and molecular docking. Clinical Journal of Traditional Chinese Medicine , 16 ( 3 ), 51 – 57 .

Yue H. X. , Long H. Y. , Wang Y. W. , Hu N. , & Luan G . X . ( 2024 ). Research progress on chemical constituents and pharmacological effects of Potentilla anserina. Northwest Pharmaceutical Journal , 39 ( 2 ), 255 – 265 .

Li A. P. , Li Y. , Xu H. Y. , Fu J. C. , & Chen Y . C . ( 2024 ). Basic research progress on Tibetan medicine for hypoxic pulmonary hypertension. Herald of Medicine , 43 ( 4 ), 545 – 549 .

Yu S. F. , Wang W. J. , Yi G. Q. , et al . ( 2026 ). Research progress on pharmacological effects and mechanisms of Tibetan medicine in prevention and treatment of high altitude diseases . Pharmacology and Clinics of Chinese Materia Medica .

Huang F. F. , Li Y. Z. , Zhang T. , Wang L. X. , & Huang X . Y . ( 2018 ). Salidroside prevents hypoxic pulmonary hypertension in rats by inhibiting oxidative stress. Chinese Journal of Pathophysiology , 34 ( 3 ), 500 – 506 .

Zhou Z. G. , Zhou Y. , & Chang Z . Y . ( 2021 ). Salidroside regulates hypoxia-induced pulmonary hypertension in rats by targeting the VEGF/HIF-1α signaling pathway. Guangxi Medical Journal , 43 ( 23 ), 2834 – 2837, 2866 .

Zhang X. B. , Gao B. A. , Yang J. H. , Xiao Y. , Cao M. , & Chen S . X . ( 2012 ). Effects of Cordyceps sinensis on plasma brain natriuretic peptide and inflammatory cytokines in rats with hypoxic pulmonary hypertension. Journal of Practical Medicine , 28 ( 19 ), 3181 – 3183 .

Yu L. H. , & Lin W . ( 2013 ). Chemical constituents, pharmacological effects and clinical application of Cordyceps sinensis . Strait Pharmaceutical Journal , 25 ( 12 ), 63 – 66 .

Sheng Y. L. , Gong X. W. , Li Z. J. , Zhang X. , Tian T. , & Yuan Y . D . ( 2024 ). Mechanism of crocin alleviating right ventricular injury in rats with monocrotaline-induced pulmonary arterial hypertension . Chinese Journal of Pathophysiology , 40 ( 2 ), 221 – 229 .

Fakhri S. , Hannon K. , Peterson L. , et al . ( 2020 ). Residence at moderately high altitude and its relationship with WHO Group 1 pulmonary arterial hypertension symptom severity and clinical characteristics: the Pulmonary Hypertension Association Registry . Pulmonary Circulation , 10 ( 4 ), 1 – 8 .

Shi H. X. , Zhao Y. F. , Li S. , Wu H. T. , & Hou M . ( 2024 ). Effects of leaving low-pressure hypoxic environment on pulmonary vascular remodeling and TNF-α expression in rats with high altitude pulmonary hypertension . Medical Science Journal of Central South China , 52 ( 5 ), 721 – 724 , 785 .

Galiè N. , Humbert M. , Vachiery J. L. , et al . ( 2016 ). 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension . European Heart Journal , 37 ( 1 ), 67 – 119 .

Chen S. L. , Zhang F. F. , Xu J. , et al . ( 2013 ). Pulmonary artery denervation for treatment of pulmonary arterial hypertension . Journal of the American College of Cardiology , 62 ( 12 ), 1092 – 1100 .

Humbert M. , Kovacs G. , Hoeper M. M. , et al . ( 2022 ). 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension . European Heart Journal , 43 ( 38 ), 3618 – 3731 .

Cai L. W. , Cheng J. T. , Sun Z. R. , Guo X. Y. , Wu Y. F. , & Zhang J . J . ( 2022 ). Efficacy and safety of balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension. Chinese Journal of Interventional Cardiology , 30 ( 12 ), 898 – 902 .

Liao M. Y. , Gao X. L. , Liang W. , Huang K. , & Liu D . F . ( 2023 ). Clinical significance and technical points of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension. Journal of Clinical Cardiology , 39 ( 2 ), 88 – 92 .

Xing B. , Zhao L. , Guo L. J. , et al . ( 2025 ). Summary and analysis of cardiac function recovery after lung transplantation in patients with end-stage pulmonary hypertension . Practical Journal of Organ Transplantation , 13 ( 2 ), 141 – 146 .

Jin X. H. , Sun Y. X. , Ma J. E. , et al . ( 2025 ). Annual review of clinical lung transplantation research in China in 2024 . Organ Transplantation , 16 ( 3 ), 379 – 385 .